Tigris Ventures
Tigris Ventures is an unconventional seed-stage investment firm and venture incubator with access to over $20M in capital. We seek out compelling opportunities that can significantly impact healthcare and the environment. We focus on early-stage ventures, primarily in the Southern California region, with a relatively low risk that can produce a significant return on investment within two to four years. Unlike most VC firms, we invest our own capital and will entertain opportunities whose exit valuations are relatively modest, typically in the $2-20M range. Certain ventures are incubated within our facility – typically ones that we co-found. These start-ups have access to shared resources including our team of Associates, CAD capabilities, a complete development and prototyping laboratory, and a patent attorney. The most important aspects we consider include the potential impact of the innovation on quality of life or the environment, the strength of intellectual property, the ability to demonstrate proof-of-concept with a relatively low initial investment, the experience of the management team, market size and growth, regulatory and reimbursement hurdles, profit margins, and the potential for a successful exit by acquisition. During the evaluation process, we often engage prospective exit partners in preliminary discussions about the potential value of the innovation, and their appetite for acquiring the entity should it prove to be viable. By doing so, we significantly reduce overall risk and help each venture focus on meeting the most important milestones that drive value and enable a rewarding and timely exit.
Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.
Alastin Skincare develops innovative and clinically-validated skincare products that correct, protect, and maintain healthy skin for a lifetime. Their unparalleled procedure enhancement products are formulated utilizing the latest technology and are clinically tested to ensure both safety and effectiveness to reawaken the skin’s youthful processes. The company was founded in 2015 and is based in Carlsbad, California.
Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.